Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reaffirmed at Cowen and Company

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)‘s stock had its “buy” rating reissued by stock analysts at Cowen and Company in a report issued on Wednesday.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Sunday, November 5th. Robert W. Baird dropped their target price on shares of Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd. Morgan Stanley reissued an “equal weight” rating and issued a $71.00 target price (up from $69.00) on shares of Ultragenyx Pharmaceutical in a research report on Friday, October 6th. Finally, Wedbush raised shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and set a $62.00 target price on the stock in a research report on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $71.80.

Ultragenyx Pharmaceutical (NASDAQ RARE) traded up $1.77 during trading on Wednesday, hitting $47.32. 741,000 shares of the stock traded hands, compared to its average volume of 433,449. Ultragenyx Pharmaceutical has a 1-year low of $44.02 and a 1-year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting the consensus estimate of ($1.87). The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. The business’s revenue was up 81.8% on a year-over-year basis. During the same period last year, the business earned ($1.64) earnings per share. research analysts predict that Ultragenyx Pharmaceutical will post -7.24 EPS for the current year.

WARNING: “Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reaffirmed at Cowen and Company” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/15/ultragenyx-pharmaceuticals-rare-buy-rating-reaffirmed-at-cowen-and-company.html.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 7,500 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was bought at an average cost of $52.52 per share, with a total value of $393,900.00. Following the completion of the transaction, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 9.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Sei Investments Co. bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth approximately $125,000. SG Americas Securities LLC bought a new stake in Ultragenyx Pharmaceutical in the third quarter worth approximately $156,000. Tocqueville Asset Management L.P. grew its position in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 250 shares in the last quarter. Pacer Advisors Inc. grew its position in Ultragenyx Pharmaceutical by 12.0% in the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 365 shares in the last quarter. Finally, Kazazian Asset Management LLC bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth approximately $213,000. 95.97% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply